Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. Pediatr Dermatol 2025 Sep 02
Date
09/03/2025Pubmed ID
40898756DOI
10.1111/pde.70033Scopus ID
2-s2.0-105015192436 (requires institutional sign-in at Scopus site)Abstract
Dupilumab is an IL-4Rα and IL-13 inhibitor FDA-approved for the treatment of atopic dermatitis (AD) in patients 6 months and older. Guidelines recommend against live-attenuated vaccines due to limited safety data. We conducted a retrospective chart review of 233 patients aged 6 months to 10 years receiving dupilumab for AD at Children's Wisconsin, which showed that 19 received live vaccines during the study period. Four patients reported adverse events, including one requiring hospitalization. This study aims to evaluate the effects of live vaccines in children on dupilumab therapy and to assess associated adverse events, including in patients receiving their primary series of vaccines, a setting not previously described.
Author List
Bruess GES, Barry KK, Olsen GM, Foschi CM, Cook E, Liegl M, Pan AY, Lalor LAuthors
Leah Lalor MD Associate Professor in the Dermatology department at Medical College of WisconsinAmy Y. Pan PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin
